Initiative seeks innovative experimental and computational approaches to uncover neural circuits regulating immune function and identify novel therapeutic targets
Under the agreement, Apogee shareholders will receive $135.11 per share in cash, and the transaction has been unanimously approved by both companies’ boards
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Dupixent peak sales ambition raised to more than €13 billion
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
